PhRMA responds to NORD
Executive Summary
Pharmaceutical Research & Manufacturers of America maintains that its ads on the importance of patent protections for drugs to treat orphan diseases are "accurate and fair" in June 11 letter to the National Organization for Rare Diseases. "Many diseases are rare but not eligible for orphan drug status," PhRMA's response to NORD's June 6 letter states (1"The Pink Sheet" June 10, In Brief)...